Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask its Oncologic Drugs Advisory Committee at a Dec. 2 meeting whether the thyroid cancer drug should be limited to only those patients with progressive, symptomatic disease and if post-marketing studies are needed to determine the optimal dose.